Analyst Price Targets — TLSI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 15, 2024 12:04 pm | William Plovanic | Canaccord Genuity | $11.00 | $4.11 | StreetInsider | TriSalus Life Sciences, Inc. (TLSI) PT Lowered to $11 at Canaccord Genuity |
| September 16, 2024 6:06 am | Suraj Kalia | Oppenheimer | $10.00 | $4.52 | StreetInsider | Oppenheimer Starts TriSalus Life Sciences, Inc. (TLSI) at Outperform, PT $10 |
| July 2, 2024 5:51 am | William Plovanic | Canaccord Genuity | $12.00 | $5.33 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI) |
Latest News for TLSI
Guru Stock PicksBernard Horn has made the following transactions:Reduce in XSWX: BARN by 39.89%Sold out in CGAdd in TSN by 18.45%New position in HKSE:01299Stock
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced it has priced its previously announced underwritten public offering of 9,756,100 shares of its common stock at a…
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the…
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun “JJ” Desai, a member of the Board since…
TriSalus Life Sciences, Inc. (TLSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TLSI.
U.S. House Trading
No House trades found for TLSI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.